• Explore /
  • Poster
  • / Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.

Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.

Abstract Poster

Authors

null

Andrea J. Bullock

Beth Israel Deaconess Medical Center, Boston, MA

Andrea J. Bullock , Sunil R. Hingorani , Xionghua W. Wu , Ping Jiang , Dimitrios Chondros , Sihem Khelifa , Carrie Aldrich , Jie Pu , Andrew Eugene Hendifar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01839487

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4104)

DOI

10.1200/JCO.2016.34.15_suppl.4104

Abstract #

4104

Poster Bd #

96

Abstract Disclosures

Similar Posters

First Author: Sunil R. Hingorani

First Author: Darin Taverna

First Author: Sina Buchholz

First Author: Thomas Jens Ettrich